Ondine Announces Debt Financing

 
TIDMOBP 
 
Ondine Announces Debt Financing 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
May 12, 2011 
 
Ondine Announces Debt Financing 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 12, 2011) - Ondine Biomedical Inc. (the "Company" or "Ondine") 
(TSX:OBP)(AIM:OBP), a medical technology company developing photodisinfection based products, today announced 
that it has entered into a loan agreement with Carolyn Cross, Chairman, CEO and a shareholder of the Company, 
pursuant to which Ms. Cross advanced the Company C$1,500,000 (the "Loan"), demonstrating her continued support 
of the Company. 
 
The Loan is due on October 1, 2011 and is secured by a first charge on the proceeds of any future financing 
transaction. The Loan is interest free until the due date, but thereafter, the principal amount will accrue 
interest at a rate of 5% per annum payable monthly. The proceeds of the Loan will be used for the continued 
research and development of new products based on the Company's photodisinfection technology, including the 
Company's product for the reduction of ventilator-associated pneumonia (VAP) and the Company's MRSAid(TM) 
product for the decolonization of pathogenic bacteria, such as methicillin-resistant Staphylococcus aureus 
(MRSA), in the nose; for working capital; and for general corporate purposes. 
 
The loan agreement entered into by the Company and Ms. Cross constitutes a related party transaction for the 
purposes of the AIM Rules for Companies (the "Related Party Transaction"). Accordingly, the directors of the 
Company (excluding Ms. Cross), having consulted with the Company's nominated adviser, consider the terms of the 
Related Party Transaction to be fair and reasonable insofar as the Company's shareholders are concerned. 
 
The material change report in respect of this transaction was not filed at least 21 days in advance of the 
closing of the Loan as the Company was in need of the funds. The Company considers the shortened timeframe to 
be reasonable under these circumstances. 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection 
provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic 
resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development 
laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[e-mail] 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited, Nominated Adviser 
Mark Williams/Bhavesh Patel 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
Ondine Biomedical Inc.